Torrent Pharmaceuticals Analyst Review May 2026
- May 16, 2026
- Posted by: Kashish Aggarwal
- Category: News
This Torrent Pharmaceuticals analyst review for May 2026 covers the key data investors need for TORNTPHARM at its current price of Rs 3,400. Torrent Pharmaceuticals (NSE: TORNTPHARM) is a leading pharma company with a market capitalisation of approximately Rs 1,15,000 crore, known for its strong branded generic presence in India, Germany, and the US. The analyst consensus target of Rs 3,900 implies meaningful upside from current levels, and this article examines the technical levels, business performance, valuation, and key risks that will determine whether TORNTPHARM achieves that target through FY27.
Click Here – Get Free Investment Predictions
Torrent Pharmaceuticals Company Snapshot May 2026
Torrent’s India business (55 percent of revenue) grows at 12 to 14 percent YoY in chronic therapy segments (cardiology, CNS, gastroenterology). The Germany business through Heumann Pharma provides European regulatory-quality revenue diversification. The table below summarises the key data referenced in this Torrent Pharmaceuticals analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | TORNTPHARM |
| Sector | Pharmaceuticals |
| CMP (May 2026) | Rs 3,400 |
| 52 Week High | Rs 3,900 |
| 52 Week Low | Rs 2,700 |
| Market Cap | Rs 1,15,000 Crore |
| Trailing P/E | 45.00x |
| Analyst Consensus Target | Rs 3,900 |
| Bull Case Target | Rs 4,500 |
| Bear Case Target | Rs 2,800 |
Analyst Insight in This Torrent Pharmaceuticals Analyst Review
Associate Director Kunal Singla suggests watching Torrent Pharmaceuticals closely in May 2026. At the current market price of Rs 3,400, Kunal Singla flags Pharmaceuticals sector dynamics as a key driver for TORNTPHARM’s near-term price action. He notes support in the Rs 2,754 to Rs 3,230 zone and flags any sustained close above Rs 3,604 as a positive signal worth tracking. Kunal Singla’s perspective on Torrent Pharmaceuticals adds a layer of professional technical analysis to this Torrent Pharmaceuticals analyst review and is not a buy recommendation.
Technical Analysis in This Torrent Pharmaceuticals Analyst Review
At Rs 3,400, TORNTPHARM is trading within its 52-week band of Rs 2,700 to Rs 3,900. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.
Near-term support is identified in the Rs 2,754 to Rs 3,230 band while resistance is seen in the Rs 3,604 to Rs 3,650 zone. A sustained move above Rs 3,604 could open the path toward the analyst consensus of Rs 3,900.
Screen the best stocks on the Univest Screener.
Key Support and Resistance Levels
- Support Zone: Rs 2,754 to Rs 3,230 – investors tracking this Torrent Pharmaceuticals analyst review should watch for a stabilisation or bounce in this range as a potential accumulation signal.
- Resistance Zone: Rs 3,604 to Rs 3,650 – a sustained close above Rs 3,604 would be a positive breakout signal worth flagging.
- Medium-Term Target: The analyst consensus of Rs 3,900 represents the base-case upside for this Torrent Pharmaceuticals analyst review.
Business Segment Analysis
India Branded Generics (Chronic Therapy Focus)
This is the primary revenue and margin driver for Torrent Pharmaceuticals, directly supporting the earnings trajectory toward the consensus target of Rs 3,900.
Germany (Heumann Pharma) and European Operations
This segment adds scale and diversification to Torrent Pharmaceuticals’s business model and is a meaningful EPS contributor through FY27 and FY28.
US Generics and Latin America
This represents the medium-term growth frontier for Torrent Pharmaceuticals and a key re-rating catalyst for the stock over the next 12 to 24 months.
Valuation in This Torrent Pharmaceuticals Analyst Review
At Rs 3,400, Torrent Pharmaceuticals trades at a trailing P/E of 45.00x. This Torrent Pharmaceuticals analyst review presents three scenarios: a bull case of Rs 4,500 on strong earnings delivery, a base case of Rs 3,900 at consensus, and a bear case of Rs 2,800 if macro headwinds persist. Q1 FY27 results will be the first key validation point.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 4,500 | Strong earnings and sector tailwinds |
| Base Case (Consensus) | Rs 3,900 | Moderate growth, analyst consensus estimate |
| Bear Case | Rs 2,800 | Earnings miss or macro headwinds |
Trade Outlook for Torrent Pharmaceuticals
Based on the technical and fundamental analysis in this Torrent Pharmaceuticals analyst review, investors might watch TORNTPHARM near the support zone of Rs 2,754 to Rs 3,230 for potential opportunities. A flag above Rs 3,604 could suggest improving momentum toward Rs 3,900. This article uses watch-and-flag language only and does not constitute a trade recommendation.
Key Risks for Torrent Pharmaceuticals in FY27
A well-rounded Torrent Pharmaceuticals analyst review must assess downside risks. Key risks for Torrent Pharmaceuticals include a macro slowdown affecting Pharmaceuticals sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in TORNTPHARM.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Torrent Pharmaceuticals Analyst Review Verdict for 2026
This Torrent Pharmaceuticals analyst review concludes that at Rs 3,400, TORNTPHARM offers a defined risk-reward with a consensus target of Rs 3,900. The 52-week range of Rs 2,700 to Rs 3,900 provides context on the current entry point. Use this Torrent Pharmaceuticals analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on TORNTPHARM.
Frequently Asked Questions: Torrent Pharmaceuticals Analyst Review 2026
What is the analyst target for Torrent Pharmaceuticals in 2026?
The analyst consensus target is Rs 3,900, with a bull case of Rs 4,500 and a bear case of Rs 2,800. Monitor Q1 FY27 earnings for confirmation.
Is Torrent Pharmaceuticals a good investment at Rs 3,400?
At Rs 3,400 with a P/E of 45.00x and a consensus target of Rs 3,900, this Torrent Pharmaceuticals analyst review is constructive for medium to long-term investors in the Pharmaceuticals sector. Always consult a SEBI-registered advisor before investing.
What is Torrent Pharmaceuticals’s 52-week high and low?
The 52-week high is Rs 3,900 and the 52-week low is Rs 2,700. At Rs 3,400, TORNTPHARM is positioned within this range as noted in this Torrent Pharmaceuticals analyst review.
What are the key risks for Torrent Pharmaceuticals?
Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals sector.
Where can I get live data and analyst targets for Torrent Pharmaceuticals?
Track Torrent Pharmaceuticals’s live price and analyst targets on the Univest Screener alongside professional financial advice.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
